328 related articles for article (PubMed ID: 19264574)
1. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping.
Arts J; Caenepeel P; Bisschops R; Dewulf D; Holvoet L; Piessevaux H; Bourgeois S; Sifrim D; Janssens J; Tack J
Clin Gastroenterol Hepatol; 2009 Apr; 7(4):432-7. PubMed ID: 19264574
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
Penning C; Vecht J; Masclee AA
Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
[TBL] [Abstract][Full Text] [Related]
3. Octreotide therapy in dumping syndrome: Analysis of long-term results.
Didden P; Penning C; Masclee AA
Aliment Pharmacol Ther; 2006 Nov; 24(9):1367-75. PubMed ID: 17059518
[TBL] [Abstract][Full Text] [Related]
4. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
Nikou GC; Toumpanakis C; Katsiari C; Charalambopoulos D; Sfikakis PP
J Clin Rheumatol; 2007 Jun; 13(3):119-23. PubMed ID: 17551375
[TBL] [Abstract][Full Text] [Related]
5. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
Mystakidou K; Katsouda E; Tsilika E; Smyrniotis V; Vassiliou I; Tsiatas M; Vlahos L
Anticancer Res; 2006; 26(3B):2325-8. PubMed ID: 16821610
[TBL] [Abstract][Full Text] [Related]
6. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
Matulonis UA; Seiden MV; Roche M; Krasner C; Fuller AF; Atkinson T; Kornblith A; Penson R
J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome.
Deloose E; Bisschops R; Holvoet L; Arts J; De Wulf D; Caenepeel P; Lannoo M; Vanuytsel T; Andrews C; Tack J
Neurogastroenterol Motil; 2014 Jun; 26(6):803-9. PubMed ID: 24750284
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome.
Hasler WL; Soudah HC; Owyang C
J Pharmacol Exp Ther; 1996 Jun; 277(3):1359-65. PubMed ID: 8667198
[TBL] [Abstract][Full Text] [Related]
10. [Postgastrectomy dumping treated with octreotide (Sandostatin)].
Møller TD; Carlsen CU
Ugeskr Laeger; 1993 Jun; 155(23):1805-6. PubMed ID: 8317033
[TBL] [Abstract][Full Text] [Related]
11. Octreotide improves early dumping syndrome potentially through incretins: a case report.
Sato D; Morino K; Ohashi N; Ueda E; Ikeda K; Yamamoto H; Ugi S; Yamamoto H; Araki S; Maegawa H
Endocr J; 2013; 60(7):847-53. PubMed ID: 23708181
[TBL] [Abstract][Full Text] [Related]
12. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
[TBL] [Abstract][Full Text] [Related]
13. An open trial of octreotide long-acting release in the management of short bowel syndrome.
Nehra V; Camilleri M; Burton D; Oenning L; Kelly DG
Am J Gastroenterol; 2001 May; 96(5):1494-8. PubMed ID: 11374688
[TBL] [Abstract][Full Text] [Related]
14. Successful use of long-acting octreotide for intractable chronic gastrointestinal bleeding in children.
O'Meara M; Cicalese MP; Bordugo A; Ambrosi A; Hadzic N; Mieli-Vergani G
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):48-53. PubMed ID: 25162361
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of the efficacy of Octreotide LAR in the treatment of acromegaly--a yearly observation].
Bałdys-Waligórska A; Gołkowski F; Krzentowska A; Sokołowski G; Hubalewska-Dydejczyk A
Przegl Lek; 2009; 66(5):218-21. PubMed ID: 19739577
[TBL] [Abstract][Full Text] [Related]
16. The place of octreotide in the medical management of the dumping syndrome.
Scarpignato C
Digestion; 1996; 57 Suppl 1():114-8. PubMed ID: 8813487
[TBL] [Abstract][Full Text] [Related]
17. Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels.
Befon S; Mystakidou K; Lyra M; Tubanakis N; Vlahos L
Anticancer Res; 2000; 20(5C):4039-46. PubMed ID: 11268498
[TBL] [Abstract][Full Text] [Related]
18. [Could delayed action flanreotide be used as substitute for octreotide in the treatment of dumping syndrome?].
Bouché O; Salmon-Ettersperger L; Frémond L; Thiéfin G; Zeitoun P
Gastroenterol Clin Biol; 1997; 21(1):84-5. PubMed ID: 9091398
[No Abstract] [Full Text] [Related]
19. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
Rosenoff SH; Gabrail NY; Conklin R; Hohneker JA; Berg WJ; Warsi G; Maloney J; Benedetto JJ; Miles EA; Zhu W; Anthony L
J Support Oncol; 2006 Jun; 4(6):289-94. PubMed ID: 16805331
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
